• The National Institute for Health and Care Excellence (NICE) has recommended the combination therapy of dabrafenib (Finlee®) and trametinib (Spexotras®) for the treatment of paediatric patients with low-grade glioma (LGG) and high-grade glioma (HGG) who have a BRAF V600E mutation. • BRAF V600E mutation is present in 15-20%2 of LGGs and in 5-10%3 of […]
Children in England and Wales with the most common paediatric brain tumour now have access to new treatment
